Paul Riley, PhD, MBA earned a PhD in biochemistry from Temple University in Philadelphia, PA, focusing on the function of coagulation factor XI. He is currently the Scientific Business Development Manager for Diagnostica Stago’s scientific marketing team. In his current role he oversees marketing and customer education initiatives in North America, specializing in addressing customer queries related to unexpectedly low anti-Xa results in patients receiving full-dose unfractionated heparin (UFH) compared to established target ranges. Throughout his career, he has engaged with numerous audiences, including laboratory professionals, pharmacists, and clinicians, discussing various aspects of hemostasis and coagulation. He also has a keen interest in collaborating with clinical pathologists, pharmacists, basic scientists, and pharmaceutical researchers to conduct studies and contribute to the advancement of hemostasis and coagulation science through publications and research endeavors.